Veligrotug

DRUG4 trials

Sponsors

Viridian Therapeutics, Inc.

Conditions

Thyroid Eye Disease

Phase 3

A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)

CompletedNCT05176639

Viridian Therapeutics, Inc.Thyroid Eye Disease

Start: 2022-11-16End: 2025-03-27Updated: 2026-08-13

An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)

CompletedNCT06021054

Viridian Therapeutics, Inc.Thyroid Eye Disease

Start: 2023-11-01End: 2025-07-25Updated: 2026-08-13

An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301

CompletedNCT06179875

Viridian Therapeutics, Inc.Thyroid Eye Disease

Start: 2024-01-31End: 2025-06-23Updated: 2026-08-14

A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

CompletedNCT06384547

Viridian Therapeutics, Inc.Thyroid Eye Disease

Start: 2024-05-23End: 2026-01-19Updated: 2026-08-13

Related Papers

FRI546 VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor In Development For Thyroid Eye Disease (TED): Pharmacodynamic Responses In Healthy Volunteers And Patients With Active TED

Journal of the Endocrine Society2023-10-011 citations

FRI545 Durability Of Treatment Response With VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor, In Patients With Thyroid Eye Disease (TED): Phase 1/2 Clinical Study

Journal of the Endocrine Society2023-10-01

Phase 1/2 Clinical Study of VRDN-001, A Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients with Thyroid Eye Disease (TED) (P3-9.001)

Neurology2023-04-254 citations

Phase 1 Safety and Pharmacodynamic Results of VRDN-001, a Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R) in Development for Thyroid Eye Disease (TED) (P3-9.007)

Neurology2023-04-252 citations